Eli Lilly reports final results from LUCENT-3 study of Omvoh

New data from Eli Lilly (LLY) showed Omvoh is the first and only interleukin-23p19 to help patients with moderately to severely active ulcerative colitis achieve sustained, long-term outcomes through four years. The results were seen across multiple symptomatic, clinical, endoscopic, histologic and quality-of-life measures, including among patients who had previously failed a biologic or advanced therapy. These data are the final results from the LUCENT-3 Phase 3 open-label extension study and will be presented at United European Gastroenterology Week, taking place Oct. 4-7 in Berlin. In LUCENT-3, the following results were observed after four years of total treatment among those who achieved clinical remission with Omvoh at one year in the Phase 3 LUCENT-2 study: 78% achieved corticosteroid-free clinical remission; 78% sustained long-term clinical remission; 81% sustained endoscopic remission, defined as an endoscopic subscore of 0 or 1; 90% achieved remission on the Inflammatory Bowel Disease Questionnaire; 66% achieved histological-endoscopic mucosal improvement, an important marker of deep inflammation resolution; 93% achieved a 3 or more-point reduction on the Urgency Numeric Rating Scale and 74% achieved UNRS of 0 or 11. The long-term safety profile in patients with moderately to severely active UC was consistent with the known safety profile of Omvoh with no new safety signals observed. Of patients who completed one year of blinded Omvoh maintenance therapy in LUCENT-2 and continued on to LUCENT-3, 12% reported a serious adverse event, while 7% discontinued treatment due to an adverse event.